Veracyte says ENZAMET trial shows Decipher Prostate test flags metastatic patients who benefit from adding docetaxel

Veracyte, Inc.

Veracyte, Inc.

VCYT

0.00
  • Veracyte disclosed results already presented at the 2026 ASCO meeting from a biomarker analysis of the Phase III ENZAMET trial.
  • The Decipher Prostate test identified metastatic prostate cancer patients likely to benefit from adding docetaxel to standard hormonal therapy.
  • Patients with lower-risk genomic profiles showed no added benefit from chemotherapy, supporting treatment de-escalation in that group.
  • The readout positions Decipher as a decision tool for selecting triplet therapy, potentially expanding clinical adoption in advanced disease.
  • Separate ASCO data in high-risk localized disease supported broader use by improving risk stratification beyond standard clinical factors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605300800BIZWIRE_USPR_____20260530_BW183615) on May 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.